Enhanced external counterpulsation for management of symptoms associated with long COVID

Enhanced external counterpulsation (EECP) as a possible therapy for Long COVID. Retrospective analysis of contemporary, consecutive patient cohort. 7 outpatient treatment centers. COVID patients. 15–35 EECP treatments. The change from baseline in 1) Patient Reported Outcome Measurement Information System (PROMIS) Fatigue; 2) Seattle Angina Questionnaire (SAQ); 3) Duke Activity Status Index (DASI); 4) 6-Minute Walk Test (6MWT); 5) Canadian Cardiovascular Society (CCS) Grade; 6) Rose Dyspnea Scale (RDS); and 7) Health (PHQ-9). Compared to baseline, the PROMIS Fatigue, SAQ, DASI, 6MWT improved by 4.63 ± 3.42 (p < 0.001), 21.44 16.54 18.08 13.82 200.00 180.14 = 0.002), respectively. CCS RDS 63% 44% patients, All patients unable work prior were able return post-therapy. significantly validated fatigue cardiovascular-related markers with